SEC Form 3 filed by new insider Hanson Bryan Michael
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 02/04/2026 | 3. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 900 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Incentive Stock Options | (1) | 08/22/2027 | Common Stock | 188 | $92.23 | D | |
| Incentive Stock Options | (1) | 08/22/2027 | Common Stock | 282 | $92.23 | D | |
| Incentive Stock Options | (1) | 12/20/2029 | Common Stock | 1,050 | $119.06 | D | |
| Incentive Stock Options | (1) | 08/21/2030 | Common Stock | 420 | $119.06 | D | |
| Incentive Stock Options | (1) | 03/18/2032 | Common Stock | 291 | $179.06 | D | |
| Incentive Stock Options | (1) | 03/18/2032 | Common Stock | 291 | $179.06 | D | |
| Non-Qualified Stock Options | (1) | 12/20/2029 | Common Stock | 1,050 | $119.06 | D | |
| Non-Qualified Stock Options | (1) | 08/21/2030 | Common Stock | 420 | $119.06 | D | |
| Non-Qualified Stock Options | (2) | 04/26/2033 | Common Stock | 4,377 | $88.67 | D | |
| Non-Qualified Stock Options | (3) | 04/22/2034 | Common Stock | 10,522 | $39.08 | D | |
| Non-Qualified Stock Options | (4) | 07/01/2035 | Common Stock | 17,392 | $29.79 | D | |
| Non-Qualified Stock Options | (5) | 01/30/2036 | Common Stock | 36,150 | $27.17 | D | |
| Restricted Stock Units | (6) | (6) | Common Stock | 1,459 | (7) | D | |
| Restricted Stock Units | (8) | (8) | Common Stock | 446 | (7) | D | |
| Restricted Stock Units | (9) | (9) | Common Stock | 7,016 | (7) | D | |
| Restricted Stock Units | (4) | (4) | Common Stock | 17,392 | (7) | D | |
| Restricted Stock Units | (10) | (10) | Common Stock | 36,152 | (7) | D | |
| Explanation of Responses: |
| 1. Vested in full. |
| 2. 2,918 shares are vested in full; the remaining 1,459 shares will vest on April 26, 2026. |
| 3. 3,507 shares are vested in full; 3,507 shares will vest on April 22, 2026 and 3,508 shares will vest on April 22, 2027. |
| 4. 5,797 shares will vest on July 1, 2026, 5,797 shares will vest on July 1, 2027 and 5,798 shares will vest on July 1, 2028. |
| 5. 36,150 shares will vest in equal installments on January 30, 2027, January 30 ,2028 and January 30, 2029. |
| 6. 1,459 shares will vest on April 26, 2026. |
| 7. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. |
| 8. 446 shares will vest on August 15, 2026. |
| 9. 7,016 shares will vest in equal installments on April 22, 2026 and April 22, 2027. |
| 10. 12,050 shares will vest on January 30, 2027; the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. |
| Remarks: |
| This Form 3 is being filed late due to unanticipated delays in receiving the Reporting Person's EDGAR codes |
| /s/ Euna Greene, attorney-in-fact for Bryan M. Hanson | 03/24/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||